Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders ; volume:4 ; number:1 ; day:5 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
Communications medicine ; 4, Heft 1 (5.1.2024), 1-11, 12.2024
- Urheber
-
Lauffer, Marlen C.
van Roon-Mom, Willeke
Aartsma-Rus, Annemieke
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s43856-023-00419-1
- URN
-
urn:nbn:de:101:1-2024031821222922297110
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lauffer, Marlen C.
- van Roon-Mom, Willeke
- Aartsma-Rus, Annemieke
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Experimental thymectomy : Possibilities and limitations
Reparative Dentistry: Possibilities and Limitations
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Possibilities and limitations of intravital imaging
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Experimental thymectomy : Possibilities and limitations
Reparative Dentistry: Possibilities and Limitations
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Possibilities and limitations of intravital imaging
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Experimental thymectomy : Possibilities and limitations
Reparative Dentistry: Possibilities and Limitations
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Possibilities and limitations of intravital imaging
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)